June 27, 2024
Overnight trading from July to provide US incentive for ASX-listers
OTC Markets is expected to launch its new OTC Overnight service on its OTCQX and OTCQB markets in early July,…
Category: Biotechnology
May 15, 2024
Argenica (ASX:AGN) provides more proof of traumatic brain injury reduction
More preclinical data showing efficacy on an animal model has Argenica further on the path toward clinical trials for traumatic brain injury.
April 29, 2024
Argenica (ASX:AGN) stroke drug judged safe for continued efficacy testing
ARG-007 trials will continue unmodified across ten Australian hospitals after no adverse events in the first five patients.
April 10, 2024
Argenica (ASX:AGN) doses first 5 stroke patients with no adverse events
Five patients have now safely been dosed and Argenica marks another milestone in pivotal second phase trials in the battle against stroke.
April 10, 2024
The virtue of patients
Argenica’s Liz Dallimore on clinical trials, cerebral tribulations, and dosing its first patient in the battle against stroke.
March 28, 2024
Argenica (ASX:AGN) doses first patient for pivotal human trial
A first dosing marks the official beginning of Phase 2 clinical trials to prove ARG-007’s efficacy in treating victims of acute ischaemic stroke.
March 25, 2024
Argenica (ASX:AGN) receives paediatric approval from FDA for infants therapeutic that aims to save lives
A Pediatric Disease Designation for Argenica’s therapeutic opens the post-clinical way for a priority review and path to market.
March 7, 2024
Immuron (ASX:IMC) looks toward pivotal Travelan trials
More positive Travelan results support progression toward Phase 3 clinical trials and a pivotal FDA registration.
October 18, 2023
Argenica (ASX:AGN) gets preclinical study grant for ARG-007
Argenica Thereapeutics have funding to bring its novel drug to reduce brain tissue death after stroke a step closer to approval.
October 11, 2023
Immuron (ASX:IMC) return record Travelan sales
Immuron expect sales to continue as retail pharmacies restock and short-term resident returns approach pre-pandemic levels.